ArticleEuropean journal of medical research2025
Association between red cell distribution width/serum albumin ratio and Parkinson's disease.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Red Cell Distribution Width-to-Albumin Ratio as an Early Predictor of Intensive Care Requirement and Mortality in Acute Pancreatitis.Medicina (Kaunas, Lithuania) · 2026Article
- Clopidogrel use is associated with an increased prevalence of Parkinson's disease, particularly among US adults with diabetes.Clinical parkinsonism & related disorders · 2026Article
- The Ratio of Red Blood Cell Distribution Width To Serum Albumin and its Association with Cardiovascular and All-Cause Mortality Risk in Diabetic Patients: A Cohort Study Using NHANES Data from 1999 to 2018.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe ratio between erythrocyte distribution width and serum albumin (RAR) has gained recognition as a novel composite biomarker for inflammatory processes, though its clinical significance in Parkinson's disease (PD) pathology requires further exploration. The purpose of this cross-sectional study was to investigate the relationship between RAR and PD.
methodsThis epidemiologic investigation utilized data from participants enrolled in the National Health and Nutrition Examination Survey (NHANES) spanning 2003-2018. Study cohorts comprised PD-diagnosed individuals and matched controls. To elucidate the RAR-PD connection, we implemented three analytical strategies: multivariable-adjusted logistic regression models incorporating sample weights, restricted cubic spline (RCS) modeling for nonlinear relationships, and stratified analyses across demographic subgroups. Comparative assessment of inflammatory biomarkers' discriminative performance was performed through ROC curve analysis, contrasting RAR against platelet-albumin ratio (PAR) and neutrophil-albumin ratio (NAR).
resultsThe analysis encompassed 31,848 adults (297 PD cases; 31,551 controls) from the NHANES database. Quantitative analysis revealed elevated RAR measurements in PD subjects compared to controls [3.28 (0.04) vs. 3.09 (0.01), P < 0.001]. Following covariate adjustment in weighted regression models, multivariable-adjusted analyses identified RAR as an independent predictor (adjusted OR = 1.40, 95% CI 1.06-1.85, P = 0.018). RCS modeling revealed nonlinear RAR-PD associations, peaking at 3.48 (inverted U-shape). Comparative ROC analysis confirmed RAR's discriminative superiority over PAR and NAR in PD detection (P < 0.05).
conclusionsAs demonstrated by the research findings, RAR is strongly and independently associated with PD. RAR may serve as an indicator or screening tool for an increased risk of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.